Fig. 3
CD90+ UCCs do not exhibit a distinct stem cell-like phenotype. a CD90+ fraction in unsorted (grey bars), CD90 enriched (dark grey bars), CD90 enriched cells after reculturing for about 7–8 population doublings (dark grey bars, shaded), CD90 depleted (white bars), and CD90 depleted cells after reculturing (white bars, shaded) in RT-112, J82, and HT-1376 as measured by flow cytometry. b Clonogenic potential in magnetically and FACS sorted CD90+ and CD90− populations from RT-112, J82, and HT-1376 cell lines shown by Giemsa staining. Colony-forming potential of single cells positive or negative for CD90 from RT-112 cells after FACS sorting. Phase-contrast microscopy, scale bars, 100 μm. c Cisplatin sensitivity was measured in unsorted and MACS sorted CD90+ and CD90− fractions of RT-112, J82, and HT-1376 by MTT assay after 72 h treatment. Untreated cells were set as 100. d Relative cisplatin sensitivity of FACS sorted CD90+ and CD90− cells from RT-112 and HT-1376 cell lines as measured by CellTiter-Glo Luminescent Cell Viability Assay after 72 h cisplatin treatment with IC50 concentrations (see Fig. 4a). Untreated cells were set as 1. Values represent the mean ± SD of quadruplicates. *P <0.05; **P <0.001